Aylin Yucel
About Aylin Yucel
Aylin Yucel is the WW HEOR Director-Hematology at Bristol Myers Squibb with over 20 years of diverse experience in the pharmaceutical industry.
Current Role at Bristol Myers Squibb
Aylin Yucel is currently serving as the WW HEOR Director-Hematology at Bristol Myers Squibb in New Jersey, United States. In this role, she develops and executes innovative worldwide health economic and outcomes research plans. Her responsibilities include real-world data generation in support of Hematology assets, leveraging over 20 years of diverse pharmaceutical experience.
Previous Experience at Amgen
Aylin Yucel held multiple positions at Amgen from 2016 to 2020 in Thousand Oaks, California. She served as Senior Manager, Pricing and Reimbursement - Hematology Pipeline, and Senior Manager, Global Health Economics. Earlier, Yucel was Health Economics Manager, focusing on evaluating health outcomes and economic impacts of hematology products. Her tenure at Amgen fortified her expertise in global health economics and strategic pricing.
Academic Background
Aylin Yucel earned her PhD in Pharmaceutical Health Outcomes & Policy from the University of Houston, reinforcing her expertise in health economics. She holds two Master's degrees from Arizona State University in Supply Chain Management and Health Services Administration. Additionally, Yucel has a Master's degree in Clinical Pharmacy from Yeditepe Üniversitesi and a Bachelor's degree in Pharmacy from Istanbul University.
Past Roles in the Pharmaceutical Sector
Prior to her current role, Aylin Yucel accumulated considerable experience in various capacities. She owned and managed Yucel Pharmacy in Yalova, Turkey. Her career also includes roles such as Pharmaceutical Sales Executive at Yilbak Tic. A.S., Oncology Sales Representative at Bristol Myers Squibb, and multiple internship positions, including at GlaxoSmithKline and Synthon.
Published Works and Professional Memberships
Yucel has contributed to academic journals such as the American Journal of Managed Care and the British Journal of Hematology. Her publications span various topics in health economics and outcomes research. She is also a member of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), underlining her engagement in professional communities dedicated to healthcare research.